Clinical parameters for HSCT patients with or without GVHD
| Case . | Age, y . | Sex . | Disease . | Donor . | Conditioning regimens . | Immunosuppressant drugs . | GVHD . | ES . | GVHD therapy . | Steroid-refractory GVHD . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 35 | M | CLL | BM | CY/TBI 12Gy | Tacrolimus short course MTX | aGVHD grade II (skin stage 3), severe cGVHD (lung score of 3) | + | PSL tacrolimus | + |
| 2 | 59 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 4) | + | PSL tacrolimus hMSC | + |
| 3 | 64 | F | T-ALL | CBT | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade II (skin stage 3) | + | PSL tacrolimus | + |
| 4 | 36 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade I (skin stage 1) | − | Topical agents | − |
| 5 | 61 | M | AML | BM | Flu/Mel/Bu | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 3) | − | PSL | − |
| 6 | 47 | M | ALL | BM | Flu/Mel/Bu | Tacrolimus short course MTX | — | − | − | − |
| 7 | 62 | F | ALL | BM | Flu/Mel/Bu | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 3) | + | PSL tacrolimus | + |
| 8 | 52 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
| 9 | 20 | M | AML | Haplo-PB | Flu/Bu/TBI 4Gy | Tacrolimus MMF, PTCy | aGVHD grade IV (skin stage 1, liver stage 4) | − | PSL tacrolimus | + |
| 10 | 58 | M | MDS | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade I (skin stage 1) | − | Topical agents | − |
| 11 | 64 | M | AML | Haplo-PB | Flu/Bu/TBI 4Gy | Tacrolimus MMF, PTCy | aGVHD grade II (skin stage 3) Severe cGVHD (lung score of 3) | + | PSL tacrolimus | + |
| 12 | 53 | M | MDS | CBT | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
| 13 | 37 | M | MDS | BM | Bu/CY | ATG, tacrolimus short course MTX | aGVHD grade I (skin stage 1) | + | Topical agents | − |
| 14 | 54 | F | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
| Case . | Age, y . | Sex . | Disease . | Donor . | Conditioning regimens . | Immunosuppressant drugs . | GVHD . | ES . | GVHD therapy . | Steroid-refractory GVHD . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 35 | M | CLL | BM | CY/TBI 12Gy | Tacrolimus short course MTX | aGVHD grade II (skin stage 3), severe cGVHD (lung score of 3) | + | PSL tacrolimus | + |
| 2 | 59 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 4) | + | PSL tacrolimus hMSC | + |
| 3 | 64 | F | T-ALL | CBT | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade II (skin stage 3) | + | PSL tacrolimus | + |
| 4 | 36 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade I (skin stage 1) | − | Topical agents | − |
| 5 | 61 | M | AML | BM | Flu/Mel/Bu | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 3) | − | PSL | − |
| 6 | 47 | M | ALL | BM | Flu/Mel/Bu | Tacrolimus short course MTX | — | − | − | − |
| 7 | 62 | F | ALL | BM | Flu/Mel/Bu | Tacrolimus short course MTX | aGVHD grade III (skin stage 1, gut stage 3) | + | PSL tacrolimus | + |
| 8 | 52 | M | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
| 9 | 20 | M | AML | Haplo-PB | Flu/Bu/TBI 4Gy | Tacrolimus MMF, PTCy | aGVHD grade IV (skin stage 1, liver stage 4) | − | PSL tacrolimus | + |
| 10 | 58 | M | MDS | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | aGVHD grade I (skin stage 1) | − | Topical agents | − |
| 11 | 64 | M | AML | Haplo-PB | Flu/Bu/TBI 4Gy | Tacrolimus MMF, PTCy | aGVHD grade II (skin stage 3) Severe cGVHD (lung score of 3) | + | PSL tacrolimus | + |
| 12 | 53 | M | MDS | CBT | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
| 13 | 37 | M | MDS | BM | Bu/CY | ATG, tacrolimus short course MTX | aGVHD grade I (skin stage 1) | + | Topical agents | − |
| 14 | 54 | F | AML | BM | Flu/Bu/TBI 4Gy | Tacrolimus short course MTX | — | − | − | − |
ATG, antithymocyte globulin; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; Bu, busulfan; CBT, cord blood transplantation; CLL, chronic lymphocytic leukemia; CY, cyclophosphamide; ES, engraftment syndrome; F, female; Flu, fludarabine; GVHD, graft-versus-host disease; Gy, Gray; hMSC, human mesenchymal stem cell; M, male; Mel, melphalan; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate; PB, peripheral blood; PSL, prednisolone; PTCy, posttransplant high-dose cyclophosphamide; TBI, total body irradiation.